



Received on 05 May 2017; received in revised form, 15 June 2017; accepted, 19 June 2017; published 30 June 2017

EVALUATION OF HEPATIC BIOMARKERS IN PREGNANT WOMEN WITH PREECLAMPSIA

Seyyed Hossein Hassanpour ^{*1} and Seyyed Zeinab Karami ²

Department of Toxicology ¹, Faculty of Pharmacy, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran.

Department of Biology ², Faculty of Basic Sciences, Yasouj University, Yasouj, Iran.

ABSTRACT: Preeclampsia is a pregnancy-related disorder and considered as one of the major reasons for infants and mothers death in developed nations. HELLP disorder is a problem related to child birth that usually happens in women with intense preeclampsia and associated with different features, including hemolysis, elevated liver enzymes, and low platelet count. Due to normal hepatic markers during pregnancy, our purpose is to examine these factors in pregnant women and their association with disorders such as preeclampsia and HELLP syndrome. This case-control study included 99 Iranian pregnant women that divided two groups including preeclamptic and normotensive pregnant women. Samples were collected from Ahvaz city. We measured liver enzymes activity (ALT, AST, and ALP), total bilirubin and direct bilirubin and blood platelets by calorimetry methods in both groups. The results showed that there was no significant difference in the platelet level in both groups. However, we found a significant difference in the serum level of ALT, AST, ALP and total bilirubin between two groups ($p < 0.05$), while the result related to direct bilirubin was not significant at the end of the study. The outcomes related to this study show that hepatic biomarkers in pregnant women with preeclampsia higher than normal pregnant women; therefore, we can predict more likely to develop HELLP syndrome in pregnant women with preeclampsia.

Keywords: Preeclampsia, HELLP, ALT, AST, Bilirubin

Correspondence to Author:
Seyyed Hossein Hassanpour

Department of Toxicology, Faculty of Pharmacy, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran.

E-mail: Dr.hossein1366@yahoo.com

INTRODUCTION: Preeclampsia is a pregnancy-related disorder and considered as one of major reasons for infants and mothers death in developed nations ¹. Some of the risk factors for the development of preeclampsia are diabetes mellitus, hypertension, obesity, and anti-phospholipid antibody syndrome ².

Each year, 585,000 women die due to complications related to pregnancy that is 95% of them in developing countries, and among them, 30% of cases are due to problems of hypertension during pregnancy and particularly preeclampsia ³. In the USA, 18% of mortality among women is related to pregnancy period and especially hypertension disorders during this period ⁴.

Generally, the definition of preeclampsia is complicated due to differences in its diagnosis, but persistence in blood pressure that occurs in 12 - 22% of pregnancies and is dependent on the type of population can be one of its reasons ⁵.

	<p>QUICK RESPONSE CODE</p>
	<p>DOI: 10.13040/IJPSR.0975-8232.IJLSR.3(6).67-70</p>
<p>Article can be accessed online on: www.ijlsr.com</p>	
<p>DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.IJLSR.3(6).67-70</p>	

Also, vascular endothelial dysfunction is the final common pathway that causes the mother's system response¹. For the example, one study was showed that in women with preeclampsia, increase in the level of soluble forms-like tyrosine kinase 1 (sFlt-1), and a decrease in PIGF levels is higher than the control group, as these changes occur several weeks before the first onset, their measurement can be a good predictor⁶. Researchers have been found that men and women, whose mothers during pregnancy have preeclampsia, likely their children develop preeclampsia later that shows the effect of genetic factors in this disorder, although not too much information in this field⁷.

Also, a study was conducted in Iran, winter and urinary tract infection were considered as risk factors for preeclampsia⁸. It has been reported that slightly changes occur in biomarkers of the liver during pregnancy, indeed in this period, the level of AST, ALT, GGT, serum bilirubin, and bile acids usually remain within the normal range; therefore any change in their level may indicate a problem⁹. HELLP disorder is a problem related to childbirth that usually happens in women with intense preeclampsia¹⁰. This syndrome occurs mainly in preterm and sometimes in during late gestation and after childbirth¹¹.

HELLP is expressed as the following three features: hemolysis elevated liver enzymes, and low platelet count¹². This syndrome is a very dangerous situation and leads to serious problems such as hemolysis, epigastria pain, a decrease of liver enzymes and thrombocytopenia in during this syndrome¹⁰. In Iran, a study conducted on preeclampsia was showed that there is a relationship between preeclampsia and Vitamin D¹³.

Also, Shahbazian *et al.*, 2014 examined the relationship between preeclampsia and hypertension and microalbuminuria¹⁴. As the women health is important during pregnancy and there are few studies on pregnancy and liver problems in Iran, we studied liver markers in pregnant women and their association with disorders such as preeclampsia and HELLP syndrome.

Also, this study was in line with our recent studies on women health, including cell cycle arrest in ovarian cancer¹⁵, the effect of purslane extract on antioxidant balance in women with type 2 diabetes

¹⁶, changes in the level of AGEs and β 2-microglobulin and imbalance of trace elements in type 2 diabetes^{17,18}.

MATERIAL AND METHODS:

Subjects: This case-control study was performed on 99 Iranian pregnant females, who divided two groups, including preeclampsia and normotensive pregnant women.

Measurements: We measured enzyme activity of liver biomarkers (ALT, AST, and ALP), total bilirubin and direct bilirubin by calorimetry method and blood platelets by Hematology Analyzer - Sysmex KX-21 in pregnant women with preeclampsia (n=50) and normotensive (n=49). HELLP syndrome among woman with preeclampsia by the following criteria: total bilirubin ≥ 0.6 mg/dl for detection of hemolysis, AST ≥ 20 IU /L, ALT ≥ 15 IU /L for the diagnosis of liver damage and blood platelet count less than 50,000 cells/ μ L.

Statistical Analysis: The data were expressed as mean \pm standard deviation. For comparison of groups was used independent t-test and Mann-Whitney test for platelet count and serum ALT, AST, ALP, total bilirubin, direct bilirubin, respectively. The different level was set at $P < 0.05$.

RESULTS: The outcomes of the present study was reported for 99 pregnant women, including preeclampsia (n=50) and normotensive (n=49) case. The summary of these results is presented in **Table 1**. The current data show that there was no significant difference in the platelet levels between normotensive pregnant and preeclampsia pregnant women.

However, we obtained the significant difference in the ALT serum level between normotensive pregnant women and preeclamptic pregnant women at the end of study ($P < 0.05$) also it was found a significant difference in the AST level between two groups ($P < 0.05$).

The evaluation of serum ALP serum level was also indicated that its level in preeclamptic pregnant women was significantly higher than normotensive pregnant women (about 2-fold) ($P < 0.05$). About bilirubin level (either direct or total), the result was confirmed that direct bilirubin level in preeclamptic

pregnant women had not obvious difference compared to normotensive pregnant women, while the level of total bilirubin in preeclamptic pregnant women was higher than normotensive pregnant women so that it was significant ($P < 0.05$).

TABLE 1: COMPARISON FACTORS RELATED TO PREECLAMPSIA IN BOTH GROUPS

Factor	Group	
	Preeclampsia (n=50)	Normotensive (n=49)
Blood platelet (cell/ μ L)	223.80 \pm 72.63	216.45 \pm 47.48
ALT (IU/L)	34.34 \pm 12.77*	14.51 \pm 3.93
AST (IU/L)	41.10 \pm 10.61*	20.55 \pm 6.82
ALP (IU/L)	397.20 \pm 174.49*	180.02 \pm 46.72
Direct bilirubin (mg/dl)	0.23 \pm 0.08	0.15 \pm 0.4
Total bilirubin (mg/dl)	0.99 \pm 0.91*	0.42 \pm 0.13

Values are expressed as mean \pm SD; comparisons were made using independent t-test and Mann-Whitney test for platelet count and serum ALT, AST, ALP, total bilirubin, direct bilirubin, respectively. * Significant different with Normotensive group ($P < 0.05$).

DISCUSSION: Liver function tests are abnormal in 20% to 30% of pregnancies that are associated with preeclampsia^{19, 20}, and are related poor motherhood and embryonic result^{21, 22}. Preeclampsia is a disorder with three features: proteinuria, hypertension, and edema that occur during the last trimester of 5% - 10% of pregnancies. Although the liver problem is infrequent in this disorder, nevertheless intense preeclampsia is related to perinatal illness and death. It is the most common reason of hepatic sensitivity and liver impairment in gestation period and 2% - 12% of cases will suffer from HELLP syndrome that this syndrome is expressed as the following three features: hemolysis, elevated liver enzymes, and low platelet count.

Liver involvement of preeclampsia is required no specific therapy, although the involvement is an indicator to prevent more serious disorders such as eclampsia, hepatic rupture, or necrosis²².

We studied hepatic markers and liver damage in pregnant women in both normotensive and preeclamptic group. In agreement with studies conducted by Weinstein *et al.*, 1982¹² and Shukla *et al.*, 1978²³ our data showed that there was a significant difference in the serum ALT level between normotensive pregnant women and preeclampsia pregnant women ($P < 0.05$).

Also, line with Cerutti *et al.*, 1976²⁴, Weinstein *et al.*, 1982¹² and Shukla *et al.*, 1978²³ our data indicated that there was a noticeable difference in the AST level between two groups ($P < 0.05$). Surprisingly, the current data showed that there was no significant difference in the platelet level between normotensive pregnant and preeclampsia pregnant women. But there was a significant difference in the serum ALP level and total bilirubin level between the two groups ($P < 0.05$).

The various investigations have been examined the evaluation of liver function tests and liver damage in pregnant women with preeclampsia and normal pregnant women, so that obtained different results. For example; in a study by Girling *et al.*, 1997 stated that the rate of liver function tests are less in normal gestation than the scope of reference presently used²⁵. The results of our project also revealed that more hepatic markers such as total bilirubin, ALT, and ALP in pregnant women with preeclampsia were higher than normal pregnant women. In another study on the HELLP syndrome was indicated that AST, ALT, and bilirubin were abnormal¹². We as well as found that total bilirubin and ALT level were more in pregnant women with preeclampsia, but direct bilirubin level had not a significant difference compared to normal group. It has been reported AST level abnormality more than 18 U/L²⁶, 30 U/L 52 to 57 U/L (20) 70 U/L^{24, 27}.

In normal gestation, ALT and AST are lower than non-pregnant age-matched women; however, AST changes to lesser amount²³. Based on the study of Cerutti *et al.*, 1976 AST, ALT and GGT significantly increase during the sixth month of pregnancy; however it is not obvious whether this is compared with early gestation²⁴. The primary fluctuations in liver function evaluation may be due to red cell demolition and ultimately happens liver injury²⁸. The results showed that liver damaged in pregnant women with preeclampsia. Although platelet count was nearly equal in both group, other biomarkers were higher in pregnant women with preeclampsia compared with normal pregnant women.

CONCLUSION: At the end of the study, we conclude that pregnancy with preeclampsia likely results in HELLP syndrome. We suggest further studies to understand the exact mechanism of the problem.

ACKNOWLEDGEMENT: Nil

CONFLICTS OF INTEREST: Nil

REFERENCES:

1. Leung TN, Zhang J, Lau TK, Chan LY and Lo YD: Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. *Clin Chem* 2001; 47(1): 137-9.
2. Powe CE, Levine RJ and Karumanchi SA: Preeclampsia, a disease of the maternal endothelium the role of antiangiogenic factors and implications for later cardiovascular disease. *Circulation* 2011; 123(24): 2856-69.
3. Conde-Agudelo A and Belizan JM: Risk factors for pre-eclampsia in a large cohort of Latin American and Caribbean women. *BJOG* 2000; 107(1): 75-83.
4. Leeman L and Fontaine P: Hypertensive disorders of pregnancy. *Am Fam Physician* 2008; 78(1): 93-00.
5. Sibai B, Dekker G and Kupferminc M: Preeclampsia. *The Lancet* 2005; 365(9461): 785-99.
6. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ and Yu KF: Circulating angiogenic factors and the risk of preeclampsia. *N Engl J Med* 2004; 350(7): 672-83.
7. Espin MS, Fausett MB, Fraser A, Kerber R, Mineau G and Carrillo J: Paternal and maternal components of the predisposition to preeclampsia. *N Engl J Med* 2001; 344(12): 867-72.
8. Kashanian M, Baradaran HR, Bahasadri S and Alimohammadi R: Risk factors for pre-eclampsia: a study in Tehran, Iran. *Arch Iran Med* 2011; 14(6): 412-5.
9. Riely CA: Liver disease in the pregnant patient. *Am J Gastroenterol* 1999; 94(7): 1728-32.
10. Haram K, Svendsen E and Abildgaard U: The HELLP syndrome: clinical issues and management. *A Review. BMC pregnancy and childbirth* 2009; 9:8.
11. Arulkumaran N and Lightstone L: Severe pre-eclampsia and hypertensive crises. *Best Pract Res Clin Obstet Gynaecol* 2013; 27(6): 877-84.
12. Weinstein L: Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. *Am J Obstet Gynecol* 1982; 142(2): 159-67.
13. Abedi P, Mohaghegh Z, Afshary P and Latifi M: The relationship of serum Vitamin D with pre-eclampsia in the Iranian women. *Matern Child Nutr* 2014;10(2): 206-12.
14. Shahbazian N, Shahbazian H, Ehsanpour A, Aref A and Gharibzadeh S: Hypertension and microalbuminuria 5 years after pregnancies complicated by pre-eclampsia. *Iran J Kidney Dis* 2011; 5(5): 324-7.
15. Shirali S, Aghaei M, Shabani M, Fathi M, Sohrabi M and Moeinifard M: Adenosine induces cell cycle arrest and apoptosis via cyclinD1/Cdk4 and Bcl-2/Bax pathways in human ovarian cancer cell line OVCAR-3. *Tumour Biol* 2013; 34(2): 1085-95.
16. Barari A, Fakori Joybari M, Shirali S, Shojaee M and Khandandel A: Effect of eight-week consumption of purslane extract on peroxidase/antioxidant balance in women with type 2 diabetes. *MLJ* 2014; 8(2): 1-7.
17. Sharifat M, Shirali S and Ebadi P: Investigation of changes in levels of AGEs and β 2-microglobulin in patients with type 2 diabetes. *JAAS* 2014; 4(9): 1-10.
18. Mahdizadeh R, Shirali S and Ebadi P: Investigation of imbalance of trace elements in patients with type 2 diabetes mellitus. *JAAS* 2014;4(9): 11-21.
19. Borglin N: Serum transaminase activity in uncomplicated and complicated pregnancy and newborns. *J Clin Endocrinol Metab* 1958; 18(8): 872-7.
20. Romero R, Vizoso J, Emamian M, Duffy T, Riely C and Halford T: Clinical Significance of Liver Dysfunction in Pregnancy-Induced Hypertension. *Obstetric Anesthesia Digest* 1989; 8(4): 162.
21. Verhaeghe J, Anthony J and Davey D: Platelet count and liver function tests in proteinuric and chronic hypertension in pregnancy. *S Afr Med J* 1991; 79(10): 590-4.
22. Hay JE: Liver disease in pregnancy. *Hepatology* 2008; 47(3): 1067-76.
23. Shukla P, Sharma D and Mandal R: Serum lactate dehydrogenase in detecting liver damage associated with pre-eclampsia. *Br J Obstet Gynaecol* 1978; 85(1): 40-2.
24. Cerutti R, Ferrari S, Grella P, Castelli G and Rizzotti P: Behaviour of serum enzymes in pregnancy. *Clin Exp Obstet Gynecol* 1976; 3: 22-4.
25. Girling J, Dow E and Smith J: Liver function tests in pre-eclampsia: the importance of comparison with a reference range derived for a normal pregnancy. *Br J Obstet Gynaecol* 1997; 104(2): 246-50.
26. Van DP, Renier M, Baekeland M, Buytaert P and Uyttenbroeck F: Disseminated intravascular coagulation and the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia. *Obstet Gynecol* 1989; 73(1): 97-02.
27. Goodlin R: Beware the great imitator-severe preeclampsia. *Contemp Ob Gyn* 1982; 20: 215.
28. McMahon L, O'Coighligh S and Redman C: Hepatic enzymes and the HELLP syndrome: a long-standing error? *Br J Obstet Gynaecol* 1993; 100(7): 693.

How to cite this article:

Hassanpour SH and Karami SZ: Evaluation of hepatic biomarkers in pregnant women with preeclampsia. *Int J Life Sci & Rev* 2017; 3(6): 67-70. doi: 10.13040/IJPSR.0975-8232.IJLSR.3(6).67-70.

All © 2015 are reserved by International Journal of Life Sciences and Review. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to **ANDROID OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)